Detalles de la búsqueda
1.
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Eur J Clin Pharmacol;
71(12): 1477-84, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26387812
2.
Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms.
Pharmaceutics;
14(12)2022 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36559327
3.
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Cancers (Basel);
14(12)2022 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35740506
4.
A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.
Clin Cancer Res;
24(10): 2350-2356, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29490989
5.
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Urol Oncol;
35(8): 529.e9-529.e16, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28385611
6.
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Expert Rev Mol Diagn;
16(5): 605-18, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26837796
7.
Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'.
Eur J Cancer;
138: 54-56, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854077
8.
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Eur Urol;
68(4): 621-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25930089
Resultados
1 -
8
de 8
1
Próxima >
>>